Unloxcyt (cosibelimab-ipdl) / Fortress 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   195 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Unloxcyt (cosibelimab-ipdl) / Fortress
CK-301-101, NCT03212404: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Recruiting
1
500
Europe, RoW
CK-301 (cosibelimab)
Checkpoint Therapeutics, Inc., Novotech (Australia) Pty Limited
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Classical Hodgkin Lymphoma, Cutaneous Squamous Cell Carcinoma, Non Hodgkin Lymphoma, Endometrial Cancer
11/21
12/24

Download Options